Hanmi Pharm. Co., Ltd. (KRX:128940)

Market Cap	5.43T +48.5%
Revenue (ttm)	1.55T +4.5%
Net Income	172.44B +58.3%
EPS	13,587.92 +58.2%
Shares Out	12.68M
PE Ratio	31.54
Forward PE	28.48
Dividend	1,250.00 (0.29%)
Ex-Dividend Date	Mar 30, 2026

Volume	97,128
Open	405,500
Previous Close	428,500
Day's Range	399,000 - 426,500
52-Week Range	267,500 - 647,000
Beta	0.44
Analysts	Buy
Price Target	596,666.67 (+49.17%)
Earnings Date	Jul 29, 2026

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,400
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2025, Hanmi Pharm.'s revenue was 1.55 trillion, an increase of 3.48% compared to the previous year's 1.50 trillion. Earnings were 169.55 billion, an increase of 39.76%.

Analyst Summary

According to 15 analysts, the average rating for 128940 stock is "Buy." The 12-month stock price target is ₩596,667, which is an increase of 49.17% from the latest price.

Price Target

₩596,667

(49.17% upside)

Analyst Consensus: Buy